Gómez-Acebo & Pombo and Goodwin Procter advised US-based Albany Molecular Research (AMRI) on the acquisition of Gadea Pharmaceutical Group, a privately-held company located in Valladolid, Spain.
The transaction was valued at €160 million, according to Mergermarket data.
The deal involved the issuance of 2.2 million shares of common stock – valued at $43.8 million – to Gadea’s owners, with the balance paid in cash and via the assumption of existing debt.
On a stand-alone basis, Gadea’s forecasted full year 2015 revenue is estimated to be between $80 million and $90 million.
“The acquisition of Gadea marks another milestone in our company’s path towards becoming the preeminent supplier of custom and complex drug development services and product to both the branded and generic pharmaceutical industry,” said William S. Marth, AMRI’s president and chief executive officer.